Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | August 25, 2026 | August 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date August 25, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,596 |
Ending reported balance
After 2026-08-25 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-25 · Exercise / conversion · Acquired 21,132 · Balance 52,728 Row 2 · 2026-08-25 · Exercise / conversion · Acquired 12,429 · Balance 65,157 Row 3 · 2026-08-25 · Sale · Disposed 33,561 · Balance 31,596 F1: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $194.12 · Expires 2033-05-26 | Direct | 7,044 |
Reported balance
After 2026-08-25 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-25 · Exercise / conversion · Disposed 21,132 · Balance 7,044 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $208.44 · Expires 2034-05-31 | Direct | 12,429 |
Reported balance
After 2026-08-25 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-25 · Exercise / conversion · Disposed 12,429 · Balance 12,429 |
| Common StockSEC Table I · non-derivative | Indirect2024 GRAT | 5,423 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,423 |
| Common StockSEC Table I · non-derivative | Indirect2025 GRAT | 10,780 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 10,780 |
| Common StockSEC Table I · non-derivative | Indirect2026 GRAT | 20,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 20,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 155,611 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 155,611 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust Held By Spouse | 10,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 10,000 |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2020 Filed Feb 27, 2020 19:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 25,124 | $0.00 Strike: $73.70 | $0.00 |
DisclosureSEC source: 0001127602-20-008102 · form4.xml · derivative · entry 13 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,124 shares Expires 2021-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 19:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4,896 | $164.13 | $803,576.56 |
DisclosureSEC source: 0001127602-20-008102 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,775 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $163.80 to $164.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 19:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4,198 | $163.31 | $685,562.79 |
DisclosureSEC source: 0001127602-20-008102 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,671 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $162.85 to $163.785. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 19:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 6,621 | $162.21 | $1,073,991.75 |
DisclosureSEC source: 0001127602-20-008102 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,869 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $161.84 to $162.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 19:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4,098 | $161.40 | $661,406.14 |
DisclosureSEC source: 0001127602-20-008102 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,490 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $160.85 to $161.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 19:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 5,311 | $160.40 | $851,873.78 |
DisclosureSEC source: 0001127602-20-008102 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,588 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $159.84 to $160.825. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 19:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 25,124 | $73.70 | $1,851,638.80 |
DisclosureSEC source: 0001127602-20-008102 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,899 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2020 Filed Feb 24, 2020 22:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 2,210 | $173.64 | $383,744.40 |
DisclosureSEC source: 0001127602-20-007360 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,046 Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 15:15 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 20,295 | $0.00 Strike: $109.34 | $0.00 |
DisclosureSEC source: 0001127602-20-007853 · form4.xml · derivative · entry 13 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,591 Underlying: Common Stock · 20,295 shares Expires 2023-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 15:15 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 24,008 | $0.00 Strike: $88.05 | $0.00 |
DisclosureSEC source: 0001127602-20-007853 · form4.xml · derivative · entry 12 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,009 Underlying: Common Stock · 24,008 shares Expires 2022-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 15:15 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,250 | $167.83 | $377,617.50 |
DisclosureSEC source: 0001127602-20-007853 · form4.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,250 F6 · balance_after: Held by trust of which the reporting person is trustee. These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person disclaims beneficial ownership of these securities. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 15:15 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 750 | $167.83 | $125,872.50 |
DisclosureSEC source: 0001127602-20-007853 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 750 F5 · balance_after: Held by trust of which the reporting person is trustee. The reporting person disclaims beneficial ownership of these securities. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 15:15 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,445 | $168.34 | $243,249.28 |
DisclosureSEC source: 0001127602-20-007853 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,046 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $168.08 to $169.005. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 15:15 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 6,156 | $167.44 | $1,030,761.26 |
DisclosureSEC source: 0001127602-20-007853 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,491 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $167.05 to $167.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 15:15 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 36,702 | $166.51 | $6,111,422.52 |
DisclosureSEC source: 0001127602-20-007853 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,647 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $166.035 to $167.025. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 15:15 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 20,295 | $109.34 | $2,219,055.30 |
DisclosureSEC source: 0001127602-20-007853 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 15:15 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 24,008 | $88.05 | $2,113,904.40 |
DisclosureSEC source: 0001127602-20-007853 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2020 Filed Feb 24, 2020 22:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 1,994 | $173.64 | $346,238.16 |
DisclosureSEC source: 0001127602-20-007360 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,256 Read SEC document |
| February 22, 2020 Filed Feb 24, 2020 22:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 1,814 | $173.64 | $314,982.96 |
DisclosureSEC source: 0001127602-20-007360 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,250 Read SEC document |
| February 18, 2020 Filed Feb 24, 2020 22:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-007360 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,064 Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 20:06 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 600 | $172.33 | $103,397.88 |
DisclosureSEC source: 0001127602-20-005586 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,064 F2 · price: This transaction was executed in multiple trades at prices ranging from $172.31 to $172.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 20:06 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 14,400 | $171.88 | $2,475,041.76 |
DisclosureSEC source: 0001127602-20-005586 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,664 F1 · price: This transaction was executed in multiple trades at prices ranging from $171.31 to $172.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 07, 2020 Filed Feb 10, 2020 20:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 31,824 | $159.07 | $5,062,243.68 |
DisclosureSEC source: 0001127602-20-004557 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,064 Read SEC document |
| February 07, 2020 Filed Feb 10, 2020 20:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 73,873 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004557 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,888 F1 · shares: Reflects shares of common stock. issued following the achievement of performance goals set forth in performance share unit awards originally granted on February 24, 2017. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 22:15 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 31,824 | $159.07 | $5,062,243.68 |
DisclosureSEC source: 0001127602-20-004909 · form4a.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,064 Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 22:15 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 73,873 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004909 · form4a.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,888 F1 · shares: Reflects shares of common stock, issued following the achievement of performance goals set forth in performance share unit awards originally granted on February 24,2017. Read SEC document |
| January 06, 2020 Filed Feb 10, 2020 20:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004557 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,015 Read SEC document |
| January 06, 2020 Filed Feb 11, 2020 22:15 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004909 · form4a.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,015 Read SEC document |
| September 24, 2019 Filed Feb 7, 2020 16:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004205 · form5.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,515 F1 · balance_after: On 9/17/2019: 13,615 shares were transferred from the 2017 GRAT to Direct Holdings. F2 · balance_after: On 10/23/2019, the reporting person contributed 25,000 shares of CRL common stock to a grantor retained annuity trust for the benefit of himself and his two adult children. F3 · balance_after: On 10/08/2019: 12,200 shares were transferred from the 2018 GRAT to Direct Holdings Read SEC document |
| September 24, 2019 Filed Feb 11, 2020 22:12 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004904 · form5a.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,515 F1 · balance_after: On 9/17/2019: 13,615 shares were transferred from the 2017 GRAT to Direct Holdings. F2 · balance_after: On 10/23/2019, the reporting person contributed 25,000 shares of CRL common stock to a grantor retained annuity trust for the benefit of himself and his two adult children. F3 · balance_after: On 10/08/2019: 12,200 shares were transferred from the 2018 GRAT to Direct Holdings. Read SEC document |
| September 17, 2019 Filed Feb 7, 2020 16:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 4,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004205 · form5.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · 2017 GRAT Disclosed balance after: 0 F1 · balance_after: On 9/17/2019: 13,615 shares were transferred from the 2017 GRAT to Direct Holdings. Read SEC document |
| September 17, 2019 Filed Feb 11, 2020 22:12 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 4,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004904 · form5a.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · 2017 GRAT Disclosed balance after: 0 F1 · balance_after: On 9/17/2019: 13,615 shares were transferred from the 2017 GRAT to Direct Holdings. Read SEC document |
| July 01, 2019 Filed Feb 7, 2020 16:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004205 · form5.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,515 F1 · balance_after: On 9/17/2019: 13,615 shares were transferred from the 2017 GRAT to Direct Holdings. F2 · balance_after: On 10/23/2019, the reporting person contributed 25,000 shares of CRL common stock to a grantor retained annuity trust for the benefit of himself and his two adult children. F3 · balance_after: On 10/08/2019: 12,200 shares were transferred from the 2018 GRAT to Direct Holdings Read SEC document |
| July 01, 2019 Filed Feb 11, 2020 22:12 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004904 · form5a.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,515 F1 · balance_after: On 9/17/2019: 13,615 shares were transferred from the 2017 GRAT to Direct Holdings. F2 · balance_after: On 10/23/2019, the reporting person contributed 25,000 shares of CRL common stock to a grantor retained annuity trust for the benefit of himself and his two adult children. F3 · balance_after: On 10/08/2019: 12,200 shares were transferred from the 2018 GRAT to Direct Holdings. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 14:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 2,171 | $140.71 | $305,481.41 |
DisclosureSEC source: 0001127602-19-008813 · form4.xml · nonDerivative · entry 11 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,200 Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:22 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 169 | $142.51 | $24,084.19 |
DisclosureSEC source: 0001127602-19-009111 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,200 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:22 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $142.49 | $28,498.00 |
DisclosureSEC source: 0001127602-19-009111 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,369 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:22 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 144 | $142.45 | $20,512.80 |
DisclosureSEC source: 0001127602-19-009111 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,569 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 74 | $142.42 | $10,539.08 |
DisclosureSEC source: 0001127602-19-009108 · form4.xml · nonDerivative · entry 23 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,713 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $142.35 | $14,235.00 |
DisclosureSEC source: 0001127602-19-009108 · form4.xml · nonDerivative · entry 22 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,787 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 38 | $142.29 | $5,407.02 |
DisclosureSEC source: 0001127602-19-009108 · form4.xml · nonDerivative · entry 21 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,887 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $142.22 | $14,222.00 |
DisclosureSEC source: 0001127602-19-009108 · form4.xml · nonDerivative · entry 20 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,925 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $142.21 | $28,442.00 |
DisclosureSEC source: 0001127602-19-009108 · form4.xml · nonDerivative · entry 19 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,025 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $142.17 | $28,434.00 |
DisclosureSEC source: 0001127602-19-009108 · form4.xml · nonDerivative · entry 18 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,225 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $142.16 | $14,216.00 |
DisclosureSEC source: 0001127602-19-009108 · form4.xml · nonDerivative · entry 17 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,425 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $142.15 | $28,430.00 |
DisclosureSEC source: 0001127602-19-009108 · form4.xml · nonDerivative · entry 16 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,525 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $142.13 | $42,639.00 |
DisclosureSEC source: 0001127602-19-009108 · form4.xml · nonDerivative · entry 15 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,725 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 110 | $142.10 | $15,631.00 |
DisclosureSEC source: 0001127602-19-009108 · form4.xml · nonDerivative · entry 14 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,025 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 90 | $142.09 | $12,787.65 |
DisclosureSEC source: 0001127602-19-009108 · form4.xml · nonDerivative · entry 13 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,135 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $142.08 | $14,208.00 |
DisclosureSEC source: 0001127602-19-009108 · form4.xml · nonDerivative · entry 12 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,225 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.